NaviFUS Corp. (6872) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NaviFUS Corp. stock TWD 4.58, price TWD 17.05, that is 73.1% below the price, quality 27 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
52‑month range 14.00 TWD – 39.65 TWD · fair‑value band 3.02 TWD – 5.72 TWD · the 17.05 TWD price screens above the 4.58 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow NaviFUS in your weekly email
Every Wednesday you see whether NaviFUS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NaviFUS Corp., a medical device company, develops and sells focused ultrasound (FUS) solutions for the unmet needs in neuromedicine in Taiwan.
Show moreShow less
The company develops NaviFUS, a neuronavigator-guided transcranial FUS system that delivers focal energy into deep tissues in the brain, as well as is used in various clinical applications, such as drug delivery, neuromodulation, immuno-stimulation, and others.
It also develops NAVIRFA, a navigation system that uses optical 3D surgical tracking technology to monitor the 3D position of the needle tip during ultrasonic interventional procedures. The company was founded in 2015 and is based in Taipei, Taiwan.
Stock analysis
NaviFUS Corp. (6872) currently trades at 17.05 TWD, while our model-based Fair Value estimate is 4.58 TWD, 73% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.
Scenario range: 3.02 TWD (bear) to 5.72 TWD (bull), the price of 17.05 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
NaviFUS Corp. reported revenue of 10.5M TWD in FY2025 versus 0 TWD in FY2021. Reported net income was −148M TWD in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).
What moves the price
The share trades about 36% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −73%, 6872 screens richer than that median.
Fair Value models
Bear3.02 TWDFair Value 4.58 TWDBull5.72 TWD
Price 17.05 TWD · Downside -73.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)3.55 TWD5.39 TWD6.73 TWD52
All 1 models by family
Asset-Based
NCAV (Graham)3.55 TWD5.39 TWD6.73 TWD52
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−61.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.7%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−373.3% (2022) → −1,523.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside−73.1% · Bottom 25%
Profitability
Return on assets−23.3% · Bottom 25%
Operating margin (12 months)0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NaviFUS Corp. Fair Value". https://www.fairvalue-calculator.com/stock/6872
Frequently asked questions
Is NaviFUS Corp. (6872) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 4.58 TWD versus a price of 17.05 TWD, about 73% lower (overvalued).
What is the fair value of 6872?
Our model-based fair value for NaviFUS Corp. is 4.58 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 17.05 TWD.
What is the quality score of 6872?
NaviFUS Corp. has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NaviFUS Corp. (6872)?
Our model-based price target is the fair value of 4.58 TWD (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 3.02 TWD, optimistic scenario 5.72 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the NaviFUS Corp. stock forecast for 2026?
Our models put fair value at 4.58 TWD, about 73% lower versus a price of 17.05 TWD (overvalued). Cautious scenario 3.02 TWD, optimistic scenario 5.72 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of NaviFUS Corp. (6872)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NaviFUS Corp. it is 4.58 TWD per share (as of Nov 4, 2026), against a price of 17.05 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is NaviFUS Corp. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 6872 trades above its calculated fair value: price 17.05 TWD, fair value 4.58 TWD, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6872?
No. The price is what the market pays today (17.05 TWD); the fair value is what the company's own numbers justify (4.58 TWD). For NaviFUS Corp. the two are 12.47 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is NaviFUS Corp. worth?
The market values NaviFUS Corp. at about 1.2B TWD (market capitalisation, as of Nov 4, 2026). Per share that is 17.05 TWD; our models calculate a fair value of 4.58 TWD per share.
What do the bullish and bearish scenarios say about 6872?
Our models span a range for NaviFUS Corp.: cautious scenario 3.02 TWD, base 4.58 TWD, optimistic 5.72 TWD per share (as of Nov 4, 2026, price 17.05 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 6872 from its 52-week high?
NaviFUS Corp. trades at 17.05 TWD, about 36% below its 52-week high of 26.75 TWD and 22% above the low of 14.00 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4.58 TWD is for.
Which stocks are comparable to NaviFUS Corp.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NaviFUS Corp. stock attractive at the current price?
The data as of Nov 4, 2026: price 17.05 TWD, calculated fair value 4.58 TWD (−73%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6872 calculated?
We run NaviFUS Corp. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 4.58 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NaviFUS Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NaviFUS Corp. (6872)?
The closing price on Nov 6, 2026 was 17.05 TWD. Our model-based fair value is 4.58 TWD, about 73% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NaviFUS Corp. right now?
The price sits above even our optimistic bull case (5.72 TWD). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3.02 TWD to 5.72 TWD) leaves room in how you read the outcome.
Key figures of NaviFUS Corp.
How large is the market capitalisation of NaviFUS Corp. (6872)?
The market capitalisation of NaviFUS Corp. is 1.2B TWD (≈ $36.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of NaviFUS Corp. (6872)?
Earnings per share at NaviFUS Corp. are −2.12 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of NaviFUS Corp. (6872)?
On an EBIT basis the return on assets of NaviFUS Corp. is −17.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does NaviFUS Corp. (6872) generate?
The free cash flow of NaviFUS Corp. is −139M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch NaviFUS Corp. in the live analysis
One click puts NaviFUS Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
